Azitra Shares Are Trading Higher After the Company Received FDA Approval to Proceed With Its Phase 1/2 Clinical Study of ATR-04.
Azitra Shares Are Trading Higher After the Company Received FDA Approval to Proceed With Its Phase 1/2 Clinical Study of ATR-04.
Azitra股票交易上升，因公司獲得FDA批准繼續進行ATR-04的第1/2期臨床研究。
Azitra Shares Are Trading Higher After the Company Received FDA Approval to Proceed With Its Phase 1/2 Clinical Study of ATR-04.
Azitra股票交易上升，因公司獲得FDA批准繼續進行ATR-04的第1/2期臨床研究。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。